Action ImmunoPrecise Antibodies - IPA

ImmunoPrecise Antibodies Ltd (IPA) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

6,50

( - )

Prix Achat

6,31

Prix Vente

6,75

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

322,831M

Clôture Veille

6,50

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

$ 372 651

Actions en circulation

49 666 372

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-9,43

Bénéfice par action (BPA)

-0,27

Chiffre d'affairess (LTM)

28,08M

Bénéfice net (LTM)

-12,25M

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partner... MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas. Show more

Secteur

Industrie

Site Web

www.mindwalkai.com

Siège social

Austin, United States

Fondé

1983

ImmunoPrecise Antibodies Ltd est coté dans le secteur de la TSX Venture Exchange avec le ticker IPA. Le dernier cours de clôture d'ImmunoPrecise Antibodies était de $6,50. Au cours de la dernière année, les actions de ImmunoPrecise Antibodies ont été négociées dans une fourchette de prix de $ 0,00 à $ 0,00.

ImmunoPrecise Antibodies compte actuellement 49 666 372 actions en circulation. La capitalisation boursière d'ImmunoPrecise Antibodies est de $322,83 million. ImmunoPrecise Antibodies a un ratio cours/bénéfice (ratio PE) de -9.43.

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA's Subsidiary BioStrand Secures Second VLAIO Research GrantIPA subsidiary BioStrand receives grant to expand LENSai platform by linking...

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics...

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with...

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from...

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03 In vivo, IND enabling evaluations of PolyTope®...

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

Traitement potentiel de la maladie de Parkinson et d'autres affections neurodégénératives IMMUNOPRECISE ANTIBODIES LTD. (la "Société" ou "IPA...

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's...

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX...

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

L'anticorps bloque l'interaction de liaison DFR/ACE2 par le biais d'un mécanisme d'action alternatif L'anticorps se lie à tous les variants...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action Binds to all tested variants of concern, likely...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

IPA - Frequently Asked Questions (FAQ)

What is the current ImmunoPrecise Antibodies Ltd share price?

The current share price of ImmunoPrecise Antibodies Ltd is $ 6,50

How many ImmunoPrecise Antibodies Ltd shares are in issue?

ImmunoPrecise Antibodies Ltd has 49 666 372 shares in issue

What is the market cap of ImmunoPrecise Antibodies Ltd?

The market capitalisation of ImmunoPrecise Antibodies Ltd is CAD 322,83M

What is the 1 year trading range for ImmunoPrecise Antibodies Ltd share price?

ImmunoPrecise Antibodies Ltd has traded in the range of $ 0,00 to $ 0,00 during the past year

What is the PE ratio of ImmunoPrecise Antibodies Ltd?

The price to earnings ratio of ImmunoPrecise Antibodies Ltd is -9,43

What is the cash to sales ratio of ImmunoPrecise Antibodies Ltd?

The cash to sales ratio of ImmunoPrecise Antibodies Ltd is 4,26

What is the registered address of ImmunoPrecise Antibodies Ltd?

The registered address for ImmunoPrecise Antibodies Ltd is Industrious 823 Congress Ave, Austin, Texas, 78701

What is the ImmunoPrecise Antibodies Ltd website address?

The website address for ImmunoPrecise Antibodies Ltd is www.mindwalkai.com

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ImmunoPrecise Antibodies Ltd (IPA)

ImmunoPrecise Antibodies Ltd (IPA) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de ImmunoPrecise Antibodies Ltd

IPA Dernières nouvelles

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

IPA - Frequently Asked Questions (FAQ)

IPA Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

ImmunoPrecise Antibodies Ltd (IPA)

ImmunoPrecise Antibodies Ltd (IPA) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de ImmunoPrecise Antibodies Ltd

IPA Dernières nouvelles

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue - Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

IPA Announces Agreement to Acquire BioStrand BV - Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

ImmunoPrecise lance le programme d'anticorps candidat TATX-112 pour le traitement du cancer et de la maladie d'Alzheimer

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer's Disease

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

ImmunoPrecise identifie un anticorps unique, le 23-H7, qui démontre une efficacité in vivo, un mécanisme d'action alternat...

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action & B...

IPA - Frequently Asked Questions (FAQ)

IPA Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Inscrivez-vous GRATUITEMENT et obtenez:

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS